Skip to content
BOLUS

Signal from the log

Typewriter Therapeutics

56 M$ · Series A · United States · Biotech

Biotech de Cambridge dans le Massachusetts et de Tokyo, sortie de l'ombre avec cette série A. Elle développe une thérapie génique non virale fondée sur des transposons, des gènes sauteurs, pilotés par ARN, pour insérer une séquence directement dans l'organisme sans passer par un vecteur viral. Deux premières applications visées, les CAR-T produites in vivo et les maladies génétiques du foie, avec des essais chez le primate non humain prévus fin 2026.

Verified

Announced on , logged by the watch of 2 September 2026.

Operation
Funding round
Announced amount
56 M$
Stage
Series A
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by AN Venture Partners , RA Capital Management , with ANRI , Gemseki , SBI US Gateway Fund

Provenance
Source edgar,endpoints
Logged on 2 September 2026
Description Written in French during the watch run. Based on the headline as relayed by the source, without reading the issuer's press release.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).